A Mendelian Randomization Analysis of 55 Genetically Predicted Metabolic Traits with Breast Cancer Survival Outcomes in the Pathways Study

Previous studies suggest associations of metabolic syndromes with breast cancer prognosis, yet the evidence is mixed. In recent years, the maturation of genome-wide association study findings has led to the development of polygenic scores (PGS) for many common traits, making it feasible to use Mendelian randomization to examine associations between metabolic traits and breast cancer outcomes. In the Pathways Study of 3,902 patients and a median follow-up time of 10.5 years, we adapted a Mendelian randomization approach to calculate PGS for 55 metabolic traits and tested their associations with seven survival outcomes. Multivariable Cox proportional hazards models were used to derive HRs and 95% confidence intervals (CI) with adjustment for covariates. The highest tertile (T3) of PGS for cardiovascular disease was associated with shorter overall survival (HR = 1.34, 95% CI = 1.11–1.61) and second primary cancer–free survival (HR = 1.31, 95% CI = 1.12–1.53). PGS for hypertension (T3) was associated with shorter overall survival (HR = 1.20, 95% CI = 1.00–1.43), second primary cancer–free survival (HR = 1.24, 95% CI = 1.06–1.45), invasive disease-free survival (HR = 1.18, 95% CI = 1.01–1.38), and disease-free survival (HR = 1.21, 95% CI = 1.04–1.39). PGS for serum cystatin C levels (T3) was associated with longer disease-free survival (HR = 0.82, 95% CI = 0.71–0.95), breast event-free survival (HR = 0.74, 95% CI = 0.61–0.91), and breast cancer–specific survival (HR = 0.72, 95% CI = 0.54–0.95). The above associations were significant at a nominal P < 0.05 level but not after correcting for multiple testing (Bonferroni P < 0.0009). Our analyses revealed notable associations of PGS for cardiovascular disease, hypertension, and cystatin C levels with breast cancer survival outcomes. These findings implicate metabolic traits in breast cancer prognosis. Significance: To our knowledge, this is the largest study of PGS for metabolic traits with breast cancer prognosis. The findings revealed significant associations of PGS for cardiovascular disease, hypertension, and cystatin C levels with several breast cancer survival outcomes. These findings implicate an underappreciated role of metabolic traits in breast cancer prognosis that would warrant further exploration.

[1]  N. Freedman,et al.  Leading Causes of Death in the US During the COVID-19 Pandemic, March 2020 to October 2021. , 2022, JAMA internal medicine.

[2]  J. Long,et al.  Mendelian randomization analyses of 23 known and suspected risk factors and biomarkers for breast cancer overall and by molecular subtypes , 2022, International journal of cancer.

[3]  C. Iribarren,et al.  Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Qianqian Zhu,et al.  UACA locus is associated with breast cancer chemoresistance and survival , 2022, NPJ breast cancer.

[5]  C. Iribarren,et al.  Risk of Cardiometabolic Risk Factors in Women With and Without a History of Breast Cancer: The Pathways Heart Study , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[7]  M. Beckmann,et al.  Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis , 2021, Scientific Reports.

[8]  Jaana M. Hartikainen,et al.  Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment , 2021, Breast Cancer Research.

[9]  R. Anderson,et al.  The Leading Causes of Death in the US for 2020. , 2021, JAMA.

[10]  S. A. Lambert,et al.  The Polygenic Score Catalog: an open database for reproducibility and systematic evaluation , 2020, medRxiv.

[11]  Gang Li,et al.  Association between metabolic syndrome and prognosis of breast cancer: a meta-analysis of follow-up studies , 2020, Diabetology & Metabolic Syndrome.

[12]  Anas M. Saad,et al.  Causes of death after breast cancer diagnosis: A US population‐based analysis , 2019, Cancer.

[13]  J. Danesh,et al.  Genomic risk score offers predictive performance comparable to clinical risk factors for ischaemic stroke , 2019, Nature Communications.

[14]  Jane E. Carpenter,et al.  Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer , 2019, Nature Communications.

[15]  A. Whittemore,et al.  Genome-wide association study of germline variants and breast cancer-specific mortality , 2019, British Journal of Cancer.

[16]  Mary E. Haas,et al.  Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations , 2018, Nature Genetics.

[17]  Mary E. Haas,et al.  Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations , 2018, Nature Genetics.

[18]  P. Fasching,et al.  Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women , 2017, Nature Communications.

[19]  K. McGlynn,et al.  Diabetes and Overall Survival among Breast Cancer Patients in the U.S. Military Health System , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[20]  Christopher R. Gignoux,et al.  Human demographic history impacts genetic risk prediction across diverse populations , 2016, bioRxiv.

[21]  Yusuke Nakamura,et al.  Cystatin C as a p53‐inducible apoptotic mediator that regulates cathepsin L activity , 2016, Cancer science.

[22]  J. Joyce,et al.  Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response , 2015, Nature Reviews Cancer.

[23]  W. Han,et al.  Prediction of Breast Cancer Survival Using Clinical and Genetic Markers by Tumor Subtypes , 2015, PloS one.

[24]  Patrick Neven,et al.  Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer , 2015 .

[25]  T. Hartley,et al.  Metabolic Syndrome Is Associated with Increased Breast Cancer Risk: A Systematic Review with Meta-Analysis , 2014, International journal of breast cancer.

[26]  F. Berrino,et al.  Metabolic syndrome and breast cancer prognosis , 2014, Breast Cancer Research and Treatment.

[27]  Wei Zheng,et al.  Novel genetic markers of breast cancer survival identified by a genome-wide association study. , 2012, Cancer research.

[28]  B. Sternfeld,et al.  The Pathways Study: a prospective study of breast cancer survivorship within Kaiser Permanente Northern California , 2008, Cancer Causes & Control.

[29]  Bonnie F. Sloane,et al.  Cysteine cathepsins in human cancer , 2004, Biological chemistry.

[30]  Izabela Berdowska,et al.  Cysteine proteases as disease markers. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[31]  Patrick Dowd,et al.  Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families , 1994, Nature Genetics.